Since there was a paucity in data evaluating the DPP-4 inhibitor drug class, from here on, more research is requisite for the DPP-4 inhibitor class in patients with T2DM without any comorbidities. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.